Drugs / HL-OCV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02823899 | Jul 2016 → Nov 2017 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL-OCV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02823899 ↗ |
| Modality | Vaccine | “The objective of this study is to determine most safe and immunogenic formulation for new oral cholera vaccine HL-OCV” NCT02823899 ↗ |
| Route | Oral | “Locally produced orally administered whole cell inactivated HL-OCV test formulations A and B” NCT02823899 ↗ |